24-Acre Minnetonka Complex Put Up for Sale by Boston Scientific (BSX)

Boston Scientific Corporation (NYSE:BSX) is one of the best stocks to buy. On June 10, the company announced that it is selling one suburban Twin Cities property and expanding another, mirroring a pattern of companies centralizing in fewer but more dynamic sites.

BSX has placed its 226,000 square foot Minnetonka campus on the market, indicating the wind-down of its presence in that suburb. Meanwhile, it is enlarging its Maple Grove operations with a new 52,000 square foot buildout at its 79-acre Weaver Lake location.

That $139.4 million development seems relatively small beside Boston Scientific’s second Maple Grove site, which is a $170 million, 400,000 square foot facility where staff are expected to begin moving in before year’s end.

A surgeon examining a patient’s brain in an operating room, paramedics nearby.

CBRE’s listing describes the Minnetonka property as containing labs, warehousing, and top-tier offices. Though no asking price is listed, county records place the combined 2025 value of four adjacent parcels at $14.8 million.

Boston Scientific employed around 10,000 people in Minnesota as of March, including sites in Minnetonka, Maple Grove, and a sizable Arden Hills facility. The number of employees has roughly doubled over 15 years. Despite its Massachusetts roots, the company runs all eight of its divisions in Minnesota, including its flagship cardiology arm.

The company did not respond to specific queries about the Minnetonka sale, including the functions housed there or implications for workforce downsizing. The real estate listing indicates the company may lease the site until mid-2026 but plans a complete exit thereafter.

Boston Scientific Corporation (NYSE:BSX), a global player in medical device innovation, operates through its Cardiovascular and MedSurg segments to deliver advanced diagnostic and therapeutic technologies.

While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.